Chromene Combination Therapy for COX-2 Targeting and Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current COX-2 inhibitors, while effective in treating cancer, can cause kidney damage and hypertension, and there is a need for a safer alternative that effectively reduces PGE2 production for cancer prevention and treatment.
Innovation Solution
A combination of deuterated and non-deuterated chromene compounds with immune checkpoint modulators such as PD-1 inhibitors, PD-L1 inhibitors, and other immune-stimulating therapies to target COX-2 and enhance immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to treat cancer, then PGE2 production is reduced and cancer treatment efficacy is improved, but kidney damage and hypertension occur
Solution Approach 1:
The patent applies parameter changes by deuterating specific positions on the chromene compound structure. This isotopic substitution alters the metabolic parameters of the drug, changing how it is processed by the body. The deuterated compounds maintain COX-2 inhibition efficacy while modifying metabolic pathways to reduce formation of harmful metabolites that cause kidney damage and hypertension.
Solution Approach 2:
The patent employs composite materials by creating deuterated chromene compounds that combine the beneficial COX-2 inhibitory properties of chromene structures with the metabolic stability provided by deuterium atoms. This composite approach integrates two functional elements: the chromene core for COX-2 binding and deuterium labels for improved metabolic profile, resulting in a drug that maintains efficacy while reducing toxicity.
2Object-affected harmful factors
If selective COX-2 inhibitors are used instead of nonselective NSAIDs, then kidney damage is reduced, but the need for combination therapy arises to enhance immune response
Solution Approach 1:
The patent merges two distinct therapeutic mechanisms: COX-2 inhibition (which reduces PGE2 production and protects kidneys) and immune checkpoint modulation (which enhances immune response against cancer). By combining a deuterated chromene COX-2 inhibitor with immune checkpoint modulators, the patent creates a synergistic treatment that addresses both the need for reduced toxicity and enhanced anti-tumor immunity.
Solution Approach 2:
The patent applies universality by designing a combination therapy regimen that simultaneously achieves multiple therapeutic goals: COX-2 inhibition for cancer treatment and PGE2 reduction, metabolic stabilization through deuterium, and immune system activation through checkpoint modulation. This multi-functional approach makes the treatment versatile, addressing both direct anti-tumor effects and immune-mediated anti-tumor responses.
Data Source
AI summary
The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein, EGFR inhibitor, HER2 inhibitor, and immune stimulating therapy and a method of using the combination for treating or preventing cancer.